SHP615
SHP615-302
Phase 3 small_molecule completed
Quick answer
SHP615 for Nervous System Diseases is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Nervous System Diseases
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed